GenieBiome identifies novel bacterial markers in stool and validates the results based on the our rich metagenome dataset. CRC
CORE TM tests are rapid and accurate for early detection of colorectal cancer (sensitivity 94%, specificity 85%) and pre-cancer lesions, adenomas (sensitivity >60%) - it overcomes the physical suffering, inconvenience, high cost and low compliance associated with colonoscopy.
CORE TM has 4 unique value propositions — non-invasive, affordable, sensitive for precancer lesions, and tailored-made with potential for risk monitoring and modulation.
CORE TM is intended to be complementary to international guideline-recommended cancer screening.
Based on survey results from 1,250 respondents from China and South East Asia, majority are willing to use CRC
CORE TM ,which is a microbiome-based and non-invasive test, that addresses the unmet needs of people aged 40+. We are supporting our pipelines with clinical trials.